ClearLight Closes Lab Services and Offers Expert Consulting Services Learn More

ClearLight Biotechnologies Announces CLARITY Tissue Clearing Kits

Posted on Oct 10, 2020

Research Use Only Kits Empower Researchers to Directly Perform Lipid Clearing of Soft Tissues

SUNNYVALE, CA., October 10, 2020 – ClearLight Biotechnologies is pleased to announce the release of CLARITY Tissue Clearing Kits. CLARITY is a tissue clearing method used to render tissues optically transparent, allowing for non-destructive tissue processing and 3D imaging of both normal and diseased soft tissues. The research use only Tissue Clearing Kits provide researchers with the ability to apply the CLARITY method directly to their own tissue samples and research.

CLARITY Tissue Clearing Kits are available in two versions: a High Lipid version for brain tissue, eye, or lymph nodes, and a Low Lipid version for kidney, most cancerous tissue, liver, or tonsil. An immunostaining buffer is also available to perform immunostaining on soft tissues after tissue clearing.

“Customers have found the CLARITY Tissue Clearing Kits to be straightforward and easy to use with clear instructions,” said Dr. Sharla White, ClearLight Vice President of Research and Development. She explained, “They are perfect for researchers who wish to gain preliminary research results prior to engaging our lab services. The kits provide researchers the opportunity to gain firsthand experience in tissue clearing using the CLARITY protocol.”

Interested preclinical researchers can procure CLARITY Tissue Clearing Kits through ClearLight’s website or through a qualified reseller. A sample kit can also be requested directly from ClearLight at

ClearLight has worked with the CLARITY method since its founding in 2015 by Karl Deisseroth MD, PhD, professor of bioengineering and psychiatry at Stanford University. Dr. Deisseroth and colleagues invented and developed CLARITY lipid-clearing techniques originally to be applied to brain tissue.

In the CLARITY tissue clearing method, the tissue is first embedded with hydrogel monomers to create a matrix scaffold, then the light scattering lipids are removed. After lipid clearing, the tissue-hydrogel hybrid is both transparent to light and permeable to molecules, enabling immunostaining and imaging using a confocal or light-sheet microscope.

ClearLight has built upon the original CLARITY protocol through reagent optimization, developed an expertise in thick tissue immunostaining penetration, and expanded beyond the brain to include spheroids, organoids, eye, lymph nodes, skin, bone, kidney, liver, tonsil and other animal tissues. CLARITY is core to ClearLight’s business. Through lab services and collaborations with customers, ClearLight continues to expand the library of tissues, optimized antibodies and applications for CLARITY. Researchers can learn more about the CLARITY method on the company’s website.

About ClearLight Biotechnologies, Inc.

Founded by Karl Deisseroth M.D., Ph.D., ClearLight Biotechnologies provides pharmaceutical, biotechnology, and academic researchers with CLARITY Tissue Clearing, 3D immunostaining, and Tru3D image analysis services. ClearLight technology is based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technology, paired with proprietary 3D image analysis software in development, empowers researchers to “See More Biology” within the tissue microenvironment. ClearLight Biotechnologies is developing technologies to improve diagnostic, prognostic, and predictive treatment of disease so we can all live healthier lives.

Learn more about ClearLight by visiting the company online at:


Contact: Al Hansen, President
(408) 329-7769




Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: